# Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

> **NCT07136389** · PHASE1 · RECRUITING · sponsor: **Biocad** · enrollment: 135 (estimated)

## Conditions studied

- Systemic Lupus Erthematosus

## Interventions

- **DRUG:** BCD-256
- **DRUG:** BCD-256
- **DRUG:** BCD-256
- **DRUG:** Divozilimab
- **DRUG:** BCD-256

## Key facts

- **NCT ID:** NCT07136389
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136389, "Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07136389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*